Patents by Inventor Andreas Kungl

Andreas Kungl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • T-CELL MOBILIZING CXCL10 MUTANT WITH INCREASED GLYCOSAMINOGLYCAN BINDING AFFINITY
    Publication number: 20220281934
    Abstract: Herein provided is a novel recombinant CXCL10 polypeptide with increased glycosaminoglycan (GAG) binding affinity compared to wild type CXCL10 and increasing T-cell mobilization and its use for preventing or treating inflammatory and immuno-logical disorders and auto-immune diseases.
    Type: Application
    Filed: August 28, 2020
    Publication date: September 8, 2022
    Inventor: Andreas KUNGL
  • Glycosaminoglycan-antagonising fusion proteins
    Patent number: 10703790
    Abstract: The present invention relates to novel monomeric fusion proteins derived from human GAG binding proteins such as chemokines with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type GAG binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: July 7, 2020
    Assignee: ANTAGONIS BIOTHERAPEUTICS GMBH
    Inventor: Andreas Kungl
  • NOVEL GLYCOSAMINOGLYCAN-ANTAGONISING FUSION PROTEINS AND METHODS OF USING SAME
    Publication number: 20180371043
    Abstract: The present invention relates to novel monomeric fusion proteins derived from human GAG binding proteins such as chemokines with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type GAG binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.
    Type: Application
    Filed: July 24, 2018
    Publication date: December 27, 2018
    Inventor: Andreas Kungl
  • Glycosaminoglycan-antagonising fusion proteins and methods of using same
    Patent number: 10047133
    Abstract: The present invention relates to novel monomeric fusion proteins derived from human GAG binding proteins such as chemokines with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type GAG binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: August 14, 2018
    Assignee: Antagonis Biotherapeutics GmbH
    Inventor: Andreas Kungl
  • NOVEL GLYCOSAMINOGLYCAN-ANTAGONISING FUSION PROTEINS AND METHODS OF USING SAME
    Publication number: 20170058012
    Abstract: The present invention relates to novel monomeric fusion proteins derived from human GAG binding proteins such as chemokines with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type GAG binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.
    Type: Application
    Filed: January 22, 2015
    Publication date: March 2, 2017
    Inventor: Andreas Kungl
  • FGFRI-BASED ANTAGONISTS WITH IMPROVED GLYCOSAMINOGLYCAN AFFINITY AND METHODS OF USING SAME
    Publication number: 20140073557
    Abstract: A novel approach for inhibiting FGF2/FGFR1-mediated signalling is presented which is based on FGFR1 mutations to introduce higher affinity for the natural GAG co-receptors into the soluble part of the FGF1 receptor, preferably into the D2/D3 domains.
    Type: Application
    Filed: March 16, 2012
    Publication date: March 13, 2014
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventors: Andreas Kungl, Martina Theuer
  • Glycosaminoglycan-antagonising MCP-1 mutants
    Patent number: 8337825
    Abstract: Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.
    Type: Grant
    Filed: July 21, 2008
    Date of Patent: December 25, 2012
    Assignee: Protaffin Biotechnologie AG
    Inventors: Andreas Kungl, Anna Maria Piccinini, Christian Weber
  • COMPOSITION FOR TREATMENT OF CXCL8-MEDIATED LUNG INFLAMMATION
    Publication number: 20120288474
    Abstract: The present invention provides a composition comprising a modified interleukin 8 (IL-8) having increased GAG binding affinity and further inhibited or down-regulated GPCR activity compared to the respective wild type IL-8 for use in preventing or treating lung inflammation with neutrophilic infiltration, for example for the prevention or treatment of chronic obstructive pulmonary disease, cystic fibrosis, severe asthma, bronchitis, broncheolitis, acute lung injury and acute respiratory distress syndrome.
    Type: Application
    Filed: September 13, 2010
    Publication date: November 15, 2012
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventors: Andreas Kungl, Jason Slingsby, Tiziana Adage, Angelika Rek
  • Chemokine-Chaperone Fusion Proteins
    Publication number: 20120052043
    Abstract: A fusion protein comprising at least one chemokine or a derivative or fragment thereof and at least one peptide derived from a chaperone. The fusion protein can be provided in a pharmaceutical preparation for the treatment of inflammatory conditions or cancer.
    Type: Application
    Filed: December 20, 2007
    Publication date: March 1, 2012
    Inventor: Andreas Kungl
  • GLYCOSAMINOGLYCAN-ANTAGONISING MCP-I MUTANTS AND METHODS OF USING SAME
    Publication number: 20120046218
    Abstract: Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.
    Type: Application
    Filed: January 29, 2010
    Publication date: February 23, 2012
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventor: Andreas Kungl
  • SDF-I-BASED GLYCOSAMINOGLYCAN ANTAGONISTS AND METHODS OF USING SAME
    Publication number: 20100298203
    Abstract: The present invention relates to novel mutants of human stromal cell-derived factor-1 which exhibit increased glycosaminoglycan (GAG) binding affinity and inhibited or down-regulated GPCR activity compared to wild type SDF-1, methods for producing these mutants and to their use for preparing medicaments for the treatment of cancer.
    Type: Application
    Filed: October 23, 2008
    Publication date: November 25, 2010
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventors: Andreas Kungl, Isa Werner, Jason Slingsby, Simi Ali, John Kirby
  • Glycosaminoglycan-antagonising MCP-1 Mutants and Methods of Using Same
    Publication number: 20100197583
    Abstract: Novel mutants of human monocyte chemoattractant protein 1 (MCP-1) with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type MCP-1, and their use for therapeutic treatment of inflammatory diseases.
    Type: Application
    Filed: July 21, 2008
    Publication date: August 5, 2010
    Applicant: PROTAFFIN BIOTECHNOLOGIE AG
    Inventors: Andreas Kungl, Anna Maria Piccinini, Christian Weber